NDAINHALATIONSPRAY, METERED
Approved
May 2015
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
3/8 — Basic
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STIOLTO RESPIMAT is a fixed-dose combination inhaler containing tiotropium bromide (long-acting muscarinic antagonist) and olodaterol (long-acting beta-2 agonist) delivered via Boehringer Ingelheim's proprietary Respimat metered-spray device. It is indicated for maintenance treatment of chronic obstructive pulmonary disease (COPD). The dual mechanism provides bronchodilation through complementary pathways to improve lung function and reduce exacerbation risk.
$432MPart D
PeakStable
4.1 years to LOEStrong established revenue base with 643,950 Part D claims in 2023 suggests stable commercial team operations, though competitive pressure (8/10) indicates ongoing market defense requirements.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on STIOLTO RESPIMAT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.